GKOS

Glaukos Announces First Quarter 2024 Financial Results

Retrieved on: 
Wednesday, May 1, 2024
Biotechnology, Health, General Health, Pharmaceutical, Optical, Health Technology, Other Science, Medical Devices, Research, Surgery, Science, GAAP, Investment, Corporation, Conference, Webcast, GKOS, Patient, IPR, EPS, Standard of care, Glaucoma, Retina

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024.
  • “Our record first quarter results reflect successful global execution of our key strategic plans,” said Thomas Burns, Glaukos chairman and chief executive officer.
  • Loss from operations in the first quarter of 2024 was $39.1 million, compared to operating loss of $33.0 million in the first quarter of 2023.
  • Non-GAAP loss from operations in the first quarter of 2024 was $32.8 million, compared to non-GAAP operating loss of $26.8 million in the first quarter of 2023.

Glaukos Announces the Release of its 2023 Sustainability Report

Retrieved on: 
Tuesday, April 16, 2024
Professional Services, Pharmaceutical, Philanthropy, Optical, Sustainability, Medical Devices, Environment, DEI (Diversity, Equity and Inclusion), Surgery, Other Philanthropy, Environmental, Social and Governance (ESG), Health, DEI, FDA, Corporation, Woman, Certification, ISO, GKOS, Patient, ESG, Idose, GHG, Workforce, Glaucoma, Retina

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report.
  • The report highlights the company’s continued commitment and progress on its key corporate sustainability initiatives.
  • The Sustainability Report can be found on the company’s website here .
  • For additional information and highlights, please see Glaukos’ 2023 Sustainability Report, which can be found on the company’s website here .

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

Retrieved on: 
Wednesday, April 10, 2024
Medical Devices, Health, Health Technology, Pharmaceutical, Optical, Biotechnology, GKOS, International, Glaucoma, Corporation, Conference, Retina

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2024 financial results after the market close on Wednesday, May 1, 2024.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2024 financial results after the market close on Wednesday, May 1, 2024.
  • The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m.
  • A link to the live webcast will be available on the company’s website at http://investors.glaukos.com .
  • To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742.

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Retrieved on: 
Wednesday, April 3, 2024
Medical Devices, Surgery, Health Technology, Health Insurance, Biotechnology, Managed Care, General Health, Pharmaceutical, Health, Optical, Retina, IOP, HCPCS, Glaucoma, Ocular hypertension, OAG, OHT, Patient, Corporation, APC, Eye, Surgeon, CPT, Travoprost, GKOS, OPPS, Idose, Medicare, CMS, Government, Intraocular pressure

The new J-code for iDose TR, J7355, is set to become effective July 1, 2024.

Key Points: 
  • The new J-code for iDose TR, J7355, is set to become effective July 1, 2024.
  • It is expected to increase patient access in the U.S. and has been published here on the CMS website.
  • “The receipt of a product-specific J-code for iDose TR supports our market access initiatives to enable broad access and coverage for patients suffering from open-angle glaucoma or ocular hypertension,” said Thomas Burns, Glaukos chairman and chief executive officer.
  • iDose TR is intended to improve the standard of care by addressing the ubiquitous patient non-compliance issues and chronic side effects associated with topical glaucoma medications.

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Monday, April 1, 2024
Research, Surgery, Medical Devices, Health Technology, Health, Pharmaceutical, General Health, Optical, Science, Retina, Glaucoma, Refractive surgery, ASCRS, Corporation, Faculty, Cataract, Society, GKOS, Convention center, Physician

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA.
  • Glaukos will be exhibiting onsite at booth #631.
  • The faculty includes Ike Ahmed, MD (Moderator); Sahar Bedrood, MD; John Berdahl, MD; Manjool Shah, MD; and Blake Williamson, MD.
  • The ASCRS Annual Meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry.

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 21, 2024
Medical Devices, Health, Health Technology, Pharmaceutical, Optical, Biotechnology, Investment, Standard of care, Conference, IPR, GAAP, Webcast, Patent, Patient, FY, Retina, EPS, Corporation, GKOS, Glaucoma

Gross margin for the fourth quarter of 2023 was approximately 77%, compared to approximately 76% in the same period in 2022.

Key Points: 
  • Gross margin for the fourth quarter of 2023 was approximately 77%, compared to approximately 76% in the same period in 2022.
  • Non-GAAP SG&A expenses for the fourth quarter of 2023 increased 22% to $62.3 million, compared to $51.1 million in the same period in 2022.
  • Loss from operations in the fourth quarter of 2023 was $38.6 million, compared to operating loss of $33.7 million in the fourth quarter of 2022.
  • Non-GAAP loss from operations in the fourth quarter of 2023 was $32.4 million, compared to non-GAAP operating loss of $27.4 million in the fourth quarter of 2022.

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

Retrieved on: 
Wednesday, January 31, 2024
Medical Devices, Health, Surgery, General Health, Pharmaceutical, Optical, Glaucoma, GKOS, Corporation, Retina, Conference, International

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2023 financial results after the market close on Wednesday, February 21, 2024.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2023 financial results after the market close on Wednesday, February 21, 2024.
  • The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m.
  • A link to the live webcast will be available on the company’s website at http://investors.glaukos.com .
  • To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742.

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

Retrieved on: 
Tuesday, January 9, 2024
Medical Devices, Health, Surgery, Pharmaceutical, Optical, Biotechnology, Corporation, Retina, GKOS, Glaucoma, Pharmaceutical industry

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2023.
  • Preliminary and unaudited total net sales for the fourth quarter and full year of 2023 are expected to be in excess of $81 million and $313 million, respectively.
  • In addition, the company reaffirms its 2024 net sales guidance range of $350 million to $360 million.

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, December 20, 2023
Health, Medical Devices, Surgery, Health Technology, Pharmaceutical, Optical, Biotechnology, Retina, Conference, GKOS, Glaucoma, Corporation

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT in San Francisco, CA.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT in San Francisco, CA.
  • A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com .

Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)

Retrieved on: 
Thursday, December 14, 2023
Pharmaceutical, Optical, General Health, Health, FDA, Medical Devices, Health Technology, Clinical Trials, NDA, Webcast, OAG, Eye, Acquisition, NYSE, Intraocular pressure, Safety, Food, Ocular hypertension, Travoprost, Corporation, IOP, Patient, Glaucoma, Nature, BID, U.S. FDA, Idose, Uveitis, Telecanthus, New Drug Application, Field line, Conference, MD, Timolol, Mercury (element), GKOS, OHT, Retina, Pharmaceutical industry, Medical device, 1870 Glaukos

“The FDA approval of iDose TR represents a significant milestone for Glaukos following an extensive pioneering journey since the inception of the original idea nearly 15 years ago.

Key Points: 
  • “The FDA approval of iDose TR represents a significant milestone for Glaukos following an extensive pioneering journey since the inception of the original idea nearly 15 years ago.
  • The FDA approval and Phase 3 data referenced below is for the slow-release iDose TR model, consistent with the company’s NDA submission and commercialization plans.
  • Alongside the iDose TR approval announcement, Glaukos is proud to introduce the iDose Your Dose Initiative.
  • ET (5:30 a.m. PT) to discuss the FDA approval of iDose TR.